To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.

Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Arms Length Body Publication (Data and statistics)
NHS England

Oct. 08 2026

Source Page: Friends and Family Test data – August 2026
Document: Friends and Family Test (FFT) data collection overview – August 2026 (Excel)
Arms Length Body Publication (FCA research)
Financial Conduct Authority

Oct. 07 2026

Source Page: PRISM Taskforce outcomes report
Document: PRISM Taskforce outcomes report (webpage)
Arms Length Body Publication (FCA research)
Financial Conduct Authority

Oct. 07 2026

Source Page: PRISM Taskforce outcomes report [pdf]
Document: PRISM Taskforce outcomes report [pdf] (PDF)
Arms Length Body Publication (Warnings)
Financial Conduct Authority

Oct. 07 2026

Source Page: Prestige Savings Group
Document: Prestige Savings Group (webpage)
Arms Length Body Publication (Warnings)
Financial Conduct Authority

Oct. 07 2026

Source Page: Selleypillar
Document: Selleypillar (webpage)
Arms Length Body Publication (Published)
NICE

Oct. 07 2026

Source Page: Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy
Publication Type: Summary PDF
Document: Download guidance (PDF) (webpage)
Arms Length Body Publication (Published)
NICE

Oct. 07 2026

Source Page: Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy
Publication Type: Supporting evidence
Document: Committee papers (PDF 829 KB) (webpage)
Arms Length Body Publication (Published)
NICE

Oct. 07 2026

Source Page: Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy
Publication Type: Summary PDF
Document: Download (PDF) (webpage)
Arms Length Body Publication (Published)
NICE

Oct. 07 2026

Source Page: Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy
Publication Type: Resource impact
Document: Resource impact template (Excel 1.4 MB) (webpage)
Arms Length Body Publication (Warnings)
Financial Conduct Authority

Oct. 06 2026

Source Page: Wyseforte Bank /wyseforte.co.uk
Document: Wyseforte Bank /wyseforte.co.uk (webpage)